Skip to main content
Vai all'homepage della Commissione europea (si apre in una nuova finestra)
italiano it
CORDIS - Risultati della ricerca dell’UE
CORDIS

Nanoassemblies for the subcutaneous self-administration of anticancer drugs

Obiettivo

To counter the predicted drastic rise of new cancer cases over the next decades and to lower the dramatic financial burden of cancer treatments on patients and healthcare systems, innovative chemotherapies with high efficacy and reduced cost represent an urgent and unmet clinical need. Despite great enthusiasm for drug-loaded anticancer nanocarriers (e.g. liposomes, nanoparticles, micelles), their bench-to-bedside translation is not straightforward. Recent disappointments during clinical trials have fuelled concerns as to whether drug-loaded nanocarriers work any better than the free drugs. Thus, significant rethinking of drug delivery from nanocarriers seems inescapable. In the context of THERMONANO, I will develop a new drug delivery strategy that will be simple, efficient, comfortable for the patient and significantly less costly. The idea is to design drug-loaded nanoassemblies that can be administered subcutaneously to enable the self-administration of all kinds of anticancer drugs, including irritant and vesicant drugs. Not only could this approach lead to more easy-to-handle chemotherapies, it could also boost the development of at-home cancer chemotherapy.

Campo scientifico (EuroSciVoc)

Parole chiave

Programma(i)

Argomento(i)

Meccanismo di finanziamento

ERC-COG - Consolidator Grant

Vedi tutti i progetti finanziati nell’ambito di questo schema di finanziamento

Invito a presentare proposte

(si apre in una nuova finestra) ERC-2017-COG

Vedi tutti i progetti finanziati nell’ambito del bando

Istituzione ospitante

CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS
Contributo netto dell'UE
€ 1 759 414,00
Indirizzo
RUE MICHEL ANGE 3
75794 Paris
Francia
Regione
Ile-de-France Ile-de-France Paris
Tipo di attività
Research Organisations
Collegamenti
Costo totale
€ 1 759 414,00

Beneficiari (1)